Search

everythinglearnresearchcommunity

for

Search:↓

Most treatments for lichen planopilaris were found to be generally unsatisfactory.

Skin symptoms are important for diagnosing and managing juvenile-onset systemic lupus erythematosus and usually get better with treatment.

New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.

Using 2% tofacitinib cream with narrowband ultraviolet B improved facial vitiligo by 70% in patients who didn't respond to previous treatments, with no side effects reported.

Consider benefits and risks of new alopecia treatments for safety.

Permanent hair loss from cicatricial alopecia is treated by reducing inflammation and managing symptoms, but regrowth in scarred areas is unlikely.

Minoxidil promotes hair regrowth in early baldness stages and prevents baldness in non-bald scalps.

Minoxidil effectively treats hair loss, especially androgenetic alopecia, but needs more research for better understanding.

The new FDA labeling rules provide more detailed drug safety information for pregnant and breastfeeding women, but more data is needed on the risks of many dermatologic drugs.

Lupus treatment requires a combination of drugs and therapies, with research needed for new options.

The document concludes that proper diagnosis and evidence-based treatments are crucial for managing hair diseases, and psychological support for patients is important.

New treatments for skin and hair disorders in women of color address unique biological differences and include specific acne medications, sunscreens, skin lighteners, and hair care adjustments.

New targeted therapies for hair loss from alopecia areata show promise, with personalized treatment expected in the future.

Most vitiligo patients in Makkah are young women, often with family history and thyroid issues.

Microsponges delivery system is a safe, versatile method for controlled drug release in various treatments.

Lichen planopilaris in men often involves scalp redness and itching, with some also having hair loss, mucosal lichen planus, or thyroid disease, and treatment improved symptoms in nearly half of the cases.

Segmental Vitiligo is a stable, early-onset form of vitiligo that responds well to early treatment and is ideal for repigmentation studies.

The document says that common skin conditions in adult women can be treated effectively, with acne being the most common and early-detected melanoma having a high survival rate.

Early treatment of acne is crucial to prevent scarring and psychological effects.

Some treatments for severe hair loss work but often have side effects, with baricitinib showing the most promise.

The analysis aims to identify the most effective and safest treatments for alopecia areata.

Only minoxidil and finasteride are FDA-approved for hair loss, with other treatments available but less effective or with side effects.

Melanocytes produce melanin; their defects cause vitiligo and hair graying, with treatments available for vitiligo.

The document concludes that the skin is a complex organ providing protection, sensation, and healing, with challenges in treating conditions like itchiness.

No FDA-approved treatments for chemotherapy-induced hair loss existed in 2006; more research was needed.

Alopecia Areata significantly lowers quality of life and current treatments are inadequate, highlighting a need for better therapies and standardized treatment protocols.

There are significant gaps and inconsistencies in diagnosing and treating alopecia areata in Greece and Italy.

A woman with systemic sclerosis developed a unique scarring hair loss combining features of systemic sclerosis and frontal fibrosing alopecia.

A teenager had both alopecia areata and vitiligo, which are rare to occur together.

No cure exists for alopecia areata, and treatments are personalized.